Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 6/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 5/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.64 |
| ▸ | SNCA | P37840 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.64 |
| ▸ | BLM | P54132 | 3/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.64 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.61 |
| ▸ | PGR | P06401 | 5/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | AR | P10275 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1043531 | 1.00 | SHBG (0.64) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL1043530 | 1.00 | SHBG (0.64) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL12957827 | 1.00 | SHBG (0.64) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL13356032 | 1.00 | SHBG (0.64) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL10698509 | 0.86 | SMN1; SMN2 (0.66) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8646615 | 0.86 | SMN1; SMN2 (0.66) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8646618 | 0.86 | SMN1; SMN2 (0.66) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL29504095 | 0.85 | SMN1; SMN2 (0.59) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL10698335 | 0.84 | HSD17B10 (0.60) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL10698341 | 0.84 | HSD17B10 (0.60) | SHBGLMNAHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450476-B2 | Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements | RICHTER GEDEON NYRT. (HU) | 2013-05-28 | — | — | US | claimed |
| US-8309712-B2 | Synthesis of drospirenone in only eight steps; claimed intermediates; readily available raw materials; simple crystallization purification; no hazardous materials; yield | RICHTER GEDEON NYRT. (HU) | 2012-11-13 | — | — | US | claimed |
| EP-1817326-B1 | INDUSTRIAL PROCESS FOR THE PREPERATION OF 17-HYDROXY -6 BETA, 7-BETA, 15-BETA, 16-BETA-BISMETHYLENE-3-OXO 17-ALPHA PREGN-4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE AND KEY INTERMEDIATES FOR THIS PROCESS | RICHTER GEDEON NYRT (HU) | 2010-05-19 | — | — | EP | claimed |
| EP-1831239-B1 | A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 BETA, 7 BETA, 15 BETA, 16 BETA -BISMETHYLENE-17 ALPHA-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID LAMBDA-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS | RICHTER GEDEON NYRT (HU) | 2010-03-24 | — | — | EP | claimed |
| US-20080200668-A1 | Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-08-21 | — | — | US | claimed |
| US-20080194812-A1 | Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-08-14 | — | — | US | claimed |
| EP-1817326-A1 | INDUSTRIAL PROCESS FOR THE PREPERATION OF 17-HYDROXY -6 BETA, 7-BETA, 15-BETA, 16-BETA-BISMETHYLENE-3-OXO 17-ALPHA PREGN-4-ENE-21-CARBOXYLIC ACID GAMMA-LACTONE AND KEY INTERMEDIATES FOR THIS PROCESS | Richter Gedeon Vegy Szeti Gy R Rt. (HU) | 2007-08-15 | — | — | EP | claimed |
| WO-2006059167-A1 | INDUSTRIAL PROCESS FOR THE PREPARATION OF 17-HYDROXY-6β,7β;15β,16β-BISMETHYLENE-3-OXO-17α-PREGN-4-ENE-21-CARBOXYLIC ACID Ϝ-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-06-08 | — | — | WO | claimed |
| EP-0150782-B1 | PROCESS FOR THE PREPARATION OF 15 ALPHA-HYDROXY ANDROST-4-ENE-3,17-DIONE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-07-04 | — | — | EP | claimed |
| EP-0150782-A2 | Process for the preparation of 15 alpha-hydroxy androst-4-ene-3,17-dione | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-08-07 | — | — | EP | claimed |
| US-8450476-B2 | Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements | RICHTER GEDEON NYRT. (HU) | 2013-05-28 | — | — | US | disclosed |
| US-8450476-B2 | Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements | RICHTER GEDEON NYRT. (HU) | 2013-05-28 | — | — | US | disclosed |
| US-8450476-B2 | Making drospirenone; chemical intermediates e.g. carbethoxy-drospirenone; industrial scale, safe (no chromium catalyst), meets purity requirements | RICHTER GEDEON NYRT. (HU) | 2013-05-28 | — | — | US | disclosed |
| US-8309712-B2 | Synthesis of drospirenone in only eight steps; claimed intermediates; readily available raw materials; simple crystallization purification; no hazardous materials; yield | RICHTER GEDEON NYRT. (HU) | 2012-11-13 | — | — | US | disclosed |
| US-8309712-B2 | Synthesis of drospirenone in only eight steps; claimed intermediates; readily available raw materials; simple crystallization purification; no hazardous materials; yield | RICHTER GEDEON NYRT. (HU) | 2012-11-13 | — | — | US | disclosed |
| EP-0150782-B1 | PROCESS FOR THE PREPARATION OF 15 ALPHA-HYDROXY ANDROST-4-ENE-3,17-DIONE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-07-04 | — | — | EP | disclosed |
| EP-0150782-B1 | PROCESS FOR THE PREPARATION OF 15 ALPHA-HYDROXY ANDROST-4-ENE-3,17-DIONE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-07-04 | — | — | EP | disclosed |
| EP-0150782-A2 | Process for the preparation of 15 alpha-hydroxy androst-4-ene-3,17-dione | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-08-07 | — | — | EP | disclosed |
| EP-0150782-A2 | Process for the preparation of 15 alpha-hydroxy androst-4-ene-3,17-dione | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-08-07 | — | — | EP | disclosed |
| EP-0150782-A2 | Process for the preparation of 15 alpha-hydroxy androst-4-ene-3,17-dione | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200668-A1 | Industrial Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene-3-Oxo-17Alpha-Pregn-4-Ene-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | HSD17B7, CYP17A1, HSD17B11 | SHBG 73/4885LMNA 2502/4885HSD17B10 45/4885 |
| US-20080194812-A1 | Process for the Preparation of 17-Hydroxy-6Beta, 7Beta; 15Beta, 16Beta-Bismethylene- 17Alpha-Pregn-4-Ene-3-One-21-Carboxylic Acid Y-Lactone and Key Intermediates for this Process | CYP17A1, HSD17B7, HSD17B11 | SHBG 57/4885LMNA 1403/4885HSD17B10 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.